SAGES 2021 Annual Meeting
Postponed to August 31 – September 3, 2021
MGM Grand
Las Vegas, NV
THE CALL FOR ABSTRACTS FOR THE
SAGES 2021 THE NEXT BIG THING (FORMERLY EMERGING TECHNOLOGY) SESSION
IS NOW CLOSED.
You are invited to submit papers to The Next Big Thing (Formerly Emerging Technology) Session of the SAGES 2021 Annual Meeting. The meeting will be held August 31 – September 3, 2021 in Las Vegas, NV at the MGM Grand.
This session is open to submissions from physicians / industry engineers / scientists / researchers. It should be used for reporting on cutting edge or emerging technologies for which formal experimental data may not yet be available. Developers and inventors are encouraged to present their own work.
IF YOU ARE PLANNING TO SUBMIT OR DISCUSS ANY IDEAS OR INVENTIONS, before you submit or discuss them, please keep in mind that discussing or displaying them at this meeting may be considered a public disclosure of the idea or invention, which can negatively affect your right to protect that idea or invention. You may also have duties to your employer relating to that idea or invention, and should discuss the impact of a disclosure with the proper representatives of your employer before you submit or discuss it.
The Next Big Thing Abstracts will be accepted until April 14, 2021 and will undergo an expedited review process. This session is appropriate for technologies that may still be under development. Since The Next Big Thing session will not include CME credit, topics are not limited to formal studies or experiments but may include description based abstracts or very preliminary results. Presentations will be 5 to 10 minutes in length. Accepted abstracts will be published in the official SAGES Final Program.
Submissions should follow the following format:
- Objective of the technology or device
- Description of the technology and method of its use or application
- Preliminary results if available
- Conclusions / future directions
- 500-word limit
If you have any questions, please contact the SAGES office at 310-437-0544 (ext. 118) or email: [email protected]